- Home
- EVAX
EVAX
Evaxion Biotech A/S
as 11-21-2024 11:34am EST
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
| Founded: | 2008 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 14.3M | IPO Year: | 2021 |
| Target Price: | $11.00 | AVG Volume (30 days): | 40.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.28 - $13.61 | Next Earning Date: | 10-31-2024 |
| Revenue: | $3,295,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 4845.21% | Revenue Growth (next year): | 30.30% |
Latest Evaxion Biotech A/S News
EVAX Breaking Stock News: Dive into EVAX Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Evaxion receives and appeals delisting determination from Nasdaq, remains committed to Nasdaq listing
Zacks Small Cap Research
9 days ago
EVAX Racks up Positive Test Results
GlobeNewswire
9 days ago
Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1
GlobeNewswire
21 days ago
Evaxion announces business update and third quarter 2024 financial results
Zacks Small Cap Research
21 days ago
EVAX Exceeds Estimates and Confirms Partnership
GlobeNewswire
24 days ago
Evaxion to announce business update and third quarter 2024 financial results on October 31
Zacks Small Cap Research
a month ago
OTC Markets Hosts Virtual Investor Presentation with Christian Kanstrup, CEO of Evaxion Biotech, and Brad Sorensen, Senior Analyst at Zacks SCR
GlobeNewswire
a month ago
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
Compare EVAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EVAX Evaxion Biotech A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.